Drug General Information (ID: DDIG5QAS80)
Drug Name			Asparaginase Erwinia chrysanthemi		Drug Info		Dienogest		Drug Info
Drug Type		Protein/peptide				Small molecule
Therapeutic Class		Antineoplastics				Contraceptives

Mechanism of Asparaginase Erwinia chrysanthemi-Dienogest Interaction (Severity Level: Moderate)
Decreased metabolism due to hepatotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Asparaginase Erwinia chrysanthemi				Dienogest
Mechanism		Hepatotoxicity				Metabolized by the liver
Key Mechanism Factor 1
		Factor Name		Hepatotoxicity
		Factor Description		Drug-induced hepatotoxicity is an acute or chronic liver injury secondary to drugs. The metabolism of drugs is reduced when the liver is damaged and fewer enzymes are synthesized by the liver.
Mechanism Description		Decreased metabolism of Dienogest caused by Asparaginase Erwinia chrysanthemi mediated hepatotoxicity

Recommended Action
Management		The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Asparlas (calaspargase pegol). Servier, Boston, MA.